Stephen J. Russell

Stephen J. Russell

Auto-generated profile, based on publicly available information

Stephen J. Russell

Department of Molecular Medicine, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2012 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SRStephen J Russell
Stephen J Russell
KPKah-Whye Peng
Kah-Whye Peng
JBJohn C Bell
John C Bell
Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.

1 April 2007 in Molecular Therapy
Verified
Journal Article
Open access
EKElizabeth Kelly
Elizabeth Kelly
SRStephen J Russell
Stephen J Russell
Since the turn of the nineteenth century, when their existence was first recognized, viruses have attracted considerable interest as possible agents of tumor destruction. Early case reports emphasized regression of cancers during naturally acquired virus infections, providing the basis for clinical trials where body fluids containing human or animal viruses were used to transmit infections to cancer patients. Most often the viruses were arrested by the host immune system and failed to impact tumor growth, but sometimes, in immunosuppressed patients, infection persisted and tumors regressed, although morbidity as a result of the infection of normal tissues was unacceptable. With the advent of rodent models and new methods for virus propagation, there were numerous attempts through the 1950s and 1960s to force the evolution of viruses with greater tumor specificity, but success was limited and many researchers abandoned the field. Technology employing reverse genetics later brought about a renewal of interest in virotherapy that allowed the generation of more potent, tumor-specific oncolytics. Here, examination of early oncolytic virotherapy before genetic engineering serves to highlight tremendous advances, yet also hints at ways to penetrate host immune defenses, a significant remaining challenge in modern virotherapy research.

1 April 2018 in Cancer Cell
Verified
Journal Article
Closed access
SRStephen J. Russell
Stephen J. Russell
GBGlen N. Barber
Glen N. Barber

26 October 2008 in Nature Medicine
Verified
Journal Article
Closed access
EKElizabeth J Kelly
Elizabeth J Kelly
EHElizabeth M Hadac
Elizabeth M Hadac
SGSuzanne Greiner
Suzanne Greiner
SRStephen J Russell
Stephen J Russell

1 July 2007 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
SRStephen J. Russell
Stephen J. Russell
KPKah-Whye Peng
Kah-Whye Peng

1 October 2001 in Blood
Verified
Journal Article
Open access
KPKah-Whye Peng
Kah-Whye Peng
GAGregory J. Ahmann
Gregory J. Ahmann
LPLinh Pham
Linh Pham
PGPhilip R. Greipp
Philip R. Greipp
RCRoberto Cattaneo
Roberto Cattaneo
SRStephen J. Russell
Stephen J. Russell
Conditionally replicating viruses are promising agents for the treatment of malignancy. Here it is shown that the live attenuated Edmonston-B vaccine strain of measles virus (MV-Edm) replicates selectively in human myeloma cells and has potent antitumor activity. In vitro, replication of MV-Edm was restricted in phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes (PBLs) but proceeded efficiently in a panel of 6 myeloma cell lines—ARH-77, RPMI 8226, JJN-3, MM1, KAS-6/1, and KMS-11—and in primary myeloma cells isolated by CD138 sorting from the bone marrow aspirates of 6 patients. MV-Edm infection induced potent cytopathic effects in these myeloma cells, resulting in the formation of multinucleated syncytia that eventually became nonviable. In contrast, syncytial formation in PHA-stimulated PBLs was minimal after MV-Edm infection. In vivo, MV-Edm was antitumorigenic and inhibited the establishment of myeloma cells as xenografts in immunocompromised mice. When injected directly into ARH-77 myeloma xenografts in the mice, MV-Edm caused complete regression of these xenografts. MV-Edm administered intravenously into the tail veins of mice also showed significant antineoplastic activity against established RPMI 8226 and ARH-77 xenografts. In particular, the ARH-77 myeloma xenografts were exquisitely sensitive to MV-Edm therapy, and tumors in all mice regressed completely. In light of its selectivity for myeloma cells and its potent antineoplastic activity against myeloma xenografts in vivo, MV-Edm merits further development for the treatment of multiple myeloma.